AzTrials
AzTrials

Osteoarthritis, HipNCT05587244

G7 Freedom Constrained Vivacit-E Liners

A study testing Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners in people with Osteoarthritis, Hip and Rheumatoid Arthritis, run by Zimmer Biomet at 10 sites in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
202 participants
Where
10 sitesUnited States
Study dates
8 May 2023to Dec 2038
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient is 18 to 80 years of age, inclusive
  • Patient is skeletally mature
  • Patient qualifies for unilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:
  • Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
  • Rheumatoid arthritis
  • High risk for dislocation
Show all 11Show fewer
  • Undergoing revision hip arthroplasty
  • Correction of functional deformity
  • In need of treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
  • Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB approved informed consent

Who cannot join

  • Patient is septic, has an active infection or has osteomyelitis at the affected joint
  • Patient has significant osteoporosis as defined by treating surgeon
  • Patient has metabolic disorder(s) which may impair bone formation
  • Patient has osteomalacia
  • Patient has distant foci of infections which may spread to the implant site
  • Patient has rapid joint destruction, marked bone loss or bone resorption on pre-operative radiographs
Show all 15Show fewer
  • Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
  • Patient is undergoing simultaneous bilateral THA
  • Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery.
  • In the opinion of the investigator, patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
  • Patient is known to be pregnant
  • The patient is in the vulnerable population group, such as
  • a prisoner
  • a known alcohol or drug abuser
  • mentally incompetent or unable to understand what participation in this study entails

Trial locations and contacts

10 sites in 1 country. Contact the study team or a site near you to ask about taking part.

10 sites in 1 country

United States10 sites
  • University of Alabama at Birmingham

    Birmingham, Alabama, 35205

  • The Ohio State University

    Columbus, Ohio, 43201

  • University of Florida Board of Trustees

    Gainesville, Florida, 32611

  • The University of Texas Health Science Center of Houston

    Houston, Texas, 77030

  • TOA Research Foundation

    Knoxville, Tennessee, 37923

  • Jersey City Medical Center, Inc

    Livingston, New Jersey, 07039

  • University of Southern California

    Los Angeles, California, 90033

  • West Virginia University

    Morgantown, West Virginia, 26506

  • Medical City Plano

    Plano, Texas, 75075

  • University of Utah

    Salt Lake City, Utah, 84108

Other trials in United States

About this study

Official title: Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

Read the detailed description

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

The primary endpoint is defined by the survival of the implant system at 10 years, which is based on removal of the study device and will be determined using the Kaplan-Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to the implant, instrumentation and/or procedure should be specified.

The secondary endpoints are the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if available).

The G7 Vivacit-E Freedom Constrained Liner is indicated for use (per IFU) as a component of a total hip prosthesis in primary and revision patients at high risk of dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability, and for whom all other options to constrained acetabular components have been considered.

Being tested
Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Medical subject headings
Osteoarthritis, Hip, Arthritis, Rheumatoid, Fractures, Ununited, Hip Fractures, Femoral Neck Fractures, Osteonecrosis, Hip Dislocation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E LinersDevice

    Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners

Study groups in NCT05587244
Study groupRoleWhat they receive
Total Hip Arthroplasty Treatment GroupExperimentalThis study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.
Receives: Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Survival of the study device

    Survival (whether or not it is still implanted in the subject) determined using Kaplan Meier method.

    Measured: 10 years

Secondary outcomes (10)
  1. Incidence of treatment-emergent Adverse Events (safety)

    Safety is assessed by monitoring the frequency and incidence of all adverse events, with particular focus on those that may be related to the study device.

    Measured: 10 years

  2. Pain and Functional Performance - Modified Harris Hip Score

    The Harris Hip Score evaluates hip function, pain, mobility and daily activity impairment after hip replacement surgery.

    The ten items in the Harris hip score consist of answer choices, awarded a number of points. There are four domains evaluated, as follows:

    • Pain - 1 item which scores between 0 and 44;
    • Function - 7 items, scores are between 0 and 47;
    • Deformity - 1 item which scores either 0 or 4;
    • Range of motion - 1 item which scores between 0 and 5.

    The overall score varies between 0 and 100, where scores closer to 0 are suggestive of impaired hip function and scores closer to 100 indicate positive outcome.

    There are four categories of hip function status:

    • <70: poor hip status;
    • 70 - 79: fair hip status;
    • 80 - 89: good hip status;
    • 90 - 100: excellent hip status.

    Measured: 10 years

  3. Pain and Functional Performance - Oxford Hip Score

    "The Oxford Hip Score is patient-reported outcome instrument which contains 12 questions on activities of daily living that assess function and residual pain in patients undergoing total hip replacement surgery.

    Grading the Oxford Hip Score 0 to 19-May indicate severe hip arthritis... 20 to 29-May indicate moderate to severe hip arthritis... 30 to 39-May indicate mild to moderate hip arthritis... 40 to 48-May indicate satisfactory joint function..." Oxford Hip Score. (n.d.) Segen's Medical Dictionary. (2011). Retrieved August 19 2022 from https://medical-dictionary.thefreedictionary.com/Oxford+Hip+Score

    Each question is scored from 0 to 4 with 4 being the best outcome. This method, when summed, produces overall scores running from 0 to 48 with 48 being the best outcome. The overall score is reached by simply summing the scores received for individual questions. This results in a continuous score ranging from 0 (most severe symptoms) to 48 (least symptoms).

    Measured: 10 years

  4. Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)

    The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death. Note: no VAS measures will be obtained if completed by phone interview.

    Measured: 10 Years

  5. Radiographic Performance evaluating radiolucency at 5 years follow-up

    X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency. Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them. Radiolucent structures appear dark or black in the radiographic image.

    Measured: 5 Years

  6. Radiographic Performance evaluating osteolysis at 5 years follow-up

    X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis. Osteolysis is a progressive condition where bone tissue is destroyed. In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.

    Measured: 5 Years

  7. Radiographic Performance evaluating atrophy/hypertrophy at 5 years follow-up

    X-rays will be evaluated for muscular atrophy/hypertrophy. An increase in total mass of a muscle is referred to as as hypertrophy, whereas a decrease in total mass of a muscle is referred to as atrophy.

    Measured: 5 Years

  8. Radiographic Performance evaluating component migration at 5 years follow-up

    X-rays will be evaluated for component migration to show the number of subjects with migration. Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.

    Measured: 5 Years

  9. Radiographic Performance evaluating device fracture at 5 years follow-up

    Radiographs will be evaluated (up to 5 years) for evidence of device fracture.

    Measured: 5 Years

  10. Radiographic Performance evaluating heterotopic ossification at 5 years follow-up

    X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification. Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).

    Measured: 5 Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2022
  2. Study start8 May 2023
  3. Primary completionDec 2037 (estimated)
  4. Study completionDec 2038 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Multicenter, Prospective, Non-controlled, Non-randomized, Consecutive series of patients, two cohort study
Masking
None (open label)
Enrolment
202 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05587244
Sponsor's protocol ID
CMG2021-36H
Status last verified
Oct 2025
First submitted
10 Oct 2022
Last updated
20 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners in people with Osteoarthritis, Hip and Rheumatoid Arthritis, run by Zimmer Biomet at 10 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 20 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Survival of the study device (time frame: 10 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in